Trade Ligand Pharmaceuticals Incorpor - LGND CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.68 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 110.78 |
| Open | 112.09 |
| 1-Year Change | 94.43% |
| Day's Range | 111.5 - 117.55 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 116.20 | 4.11 | 3.67% | 112.09 | 118.11 | 109.85 |
| Nov 20, 2024 | 110.78 | -0.02 | -0.02% | 110.80 | 111.63 | 108.61 |
| Nov 19, 2024 | 111.19 | 1.24 | 1.13% | 109.95 | 112.04 | 108.59 |
| Nov 18, 2024 | 110.97 | 1.37 | 1.25% | 109.60 | 112.60 | 108.82 |
| Nov 15, 2024 | 110.60 | -3.89 | -3.40% | 114.49 | 114.49 | 109.73 |
| Nov 14, 2024 | 115.22 | -6.74 | -5.53% | 121.96 | 124.64 | 113.22 |
| Nov 13, 2024 | 121.94 | 4.10 | 3.48% | 117.84 | 123.30 | 117.84 |
| Nov 12, 2024 | 120.15 | -2.75 | -2.24% | 122.90 | 123.32 | 115.42 |
| Nov 11, 2024 | 122.67 | 2.52 | 2.10% | 120.15 | 123.82 | 119.28 |
| Nov 8, 2024 | 120.42 | -3.78 | -3.04% | 124.20 | 125.75 | 116.32 |
| Nov 7, 2024 | 128.38 | 13.17 | 11.43% | 115.21 | 129.00 | 114.10 |
| Nov 6, 2024 | 116.77 | 5.65 | 5.08% | 111.12 | 116.77 | 109.48 |
| Nov 5, 2024 | 110.80 | 3.72 | 3.47% | 107.08 | 111.37 | 107.08 |
| Nov 4, 2024 | 109.87 | 3.13 | 2.93% | 106.74 | 110.20 | 106.57 |
| Nov 1, 2024 | 109.44 | 4.49 | 4.28% | 104.95 | 110.16 | 104.95 |
| Oct 31, 2024 | 105.03 | -3.23 | -2.98% | 108.26 | 108.41 | 102.19 |
| Oct 30, 2024 | 109.74 | -5.16 | -4.49% | 114.90 | 114.90 | 109.41 |
| Oct 29, 2024 | 115.09 | 2.30 | 2.04% | 112.79 | 115.13 | 111.29 |
| Oct 28, 2024 | 113.21 | 1.06 | 0.95% | 112.15 | 113.21 | 109.12 |
| Oct 25, 2024 | 111.63 | 2.33 | 2.13% | 109.30 | 112.84 | 109.30 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ligand Pharmaceuticals Incorpor Company profile
About Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its technologies include OmniAb Technologies, Pelican Expression Technology Platform, Captisol Technology, HepDirect, LTP, BEPro Technology Platform, and SUREtechnology Platform. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies. The Pelican Expression Technology is a scalable platform for recombinant protein production and is suited for complex, large-scale protein production. Captisol is a chemically modified cyclodextrin designed to optimize the stability of drugs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ligand Pharmaceuticals Inc. revenues increased 49% to $277.1M. Net income totaled $57.1M vs. loss of $3M. Revenues reflect Captisol segment increase of 49% to $164.3M, Milestone segment increase from $11.5M to $28.7M. Net Income reflects Gain (loss) from short-term investments decrease of 76% to $4M (expense), Other General and administrative decrease of 23% to $36.1M (expense).
Equity composition
Common Stock $.006 Par, 3/11, 33,333,3333 auth., 20,644,234 issd., less 1,118,222 shs in Treas. @ $42.3M. Insiders own 3.36%. IPO:11/92, 4.3M Class A shares @ $11 by Lehman Bros. FY'00 Q's are restated for SAB 101 adjustment. 9/05,Co. delisted from NASDAQ to OTC.11/10, 1-for-06 Reverse Stock split.
| Industry: | Pharmaceuticals (NEC) |
3911 Sorrento Valley Blvd
Suite 110
SAN DIEGO
CALIFORNIA 92121
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com